| scholarly article | Q13442814 |
| P50 | author | Amalia Gastaldelli | Q43294287 |
| Carla Perego | Q46052492 | ||
| Stefano La Rosa | Q46052506 | ||
| P2093 | author name string | Francesco Andreozzi | |
| Ralph A DeFronzo | |||
| Anthony G Comuzzie | |||
| Giuseppe Daniele | |||
| Paolo Fiorina | |||
| Teresa Vanessa Fiorentino | |||
| Livio Luzi | |||
| Edward J Dick | |||
| Franco Folli | |||
| Alberto O Chavez | |||
| Fausto Sessa | |||
| Raul A Bastarrachea | |||
| Alberto M Davalli | |||
| Giovanna Finzi | |||
| Eliana S Di Cairano | |||
| Alessandro Marando | |||
| Francesca Casiraghi | |||
| Glenn A Halff | |||
| Paul B Higgins | |||
| Rodolfo Guardado-Mendoza | |||
| Andrea Ricotti | |||
| Subhash Kamath | |||
| Gregory A Abrahamian | |||
| Patrice Frost | |||
| Ana M Paez | |||
| P2860 | cites work | Glucagon-like peptide analogues for type 2 diabetes mellitus | Q24235918 |
| The unique cytoarchitecture of human pancreatic islets has implications for islet cell function | Q24541464 | ||
| Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay | Q24600478 | ||
| One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial | Q24656644 | ||
| Pharmacology, physiology, and mechanisms of incretin hormone action | Q27021545 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Effect of chloroquine on cultured fibroblasts: Release of lysosomal hydrolases and inhibition of their uptake | Q28308075 | ||
| Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 | ||
| Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans | Q33755056 | ||
| Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
| Altered insulin receptor signalling and β-cell cycle dynamics in type 2 diabetes mellitus | Q34091221 | ||
| Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials | Q34124353 | ||
| Type I diabetes mellitus. A chronic autoimmune disease | Q34181699 | ||
| Glucose clamp technique: a method for quantifying insulin secretion and resistance | Q34191986 | ||
| Exendin-4 protects oxidative stress-induced β-cell apoptosis through reduced JNK and GSK3β activity | Q34255639 | ||
| Eight week exposure to a high sugar high fat diet results in adiposity gain and alterations in metabolic biomarkers in baboons (Papio hamadryas sp.). | Q34335384 | ||
| Beta-cell selective K(ATP)-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity. | Q34367701 | ||
| Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes | Q34393377 | ||
| Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates | Q34780873 | ||
| The glial glutamate transporter 1 (GLT1) is expressed by pancreatic beta-cells and prevents glutamate-induced beta-cell death | Q34800004 | ||
| Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes | Q35179964 | ||
| Quantitative study of insulin secretion and clearance in normal and obese subjects | Q35809498 | ||
| Five stages of evolving beta-cell dysfunction during progression to diabetes | Q35961960 | ||
| Relationship between beta-cell mass and diabetes onset. | Q36034329 | ||
| beta-cell failure in diabetes and preservation by clinical treatment | Q36757992 | ||
| Alterations in energy balance following exenatide administration | Q36758533 | ||
| Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver | Q37066877 | ||
| The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism. | Q37139985 | ||
| Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons | Q37172937 | ||
| Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons | Q37310707 | ||
| GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice. | Q38773675 | ||
| The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. | Q39283204 | ||
| Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway | Q40016200 | ||
| Expression of the receptor tyrosine kinase KIT in mature beta-cells and in the pancreas in development | Q40783647 | ||
| Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. | Q41015653 | ||
| Beta-cell rest: a strategy for the prevention of autoimmune diabetes | Q41740281 | ||
| Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy | Q42498875 | ||
| Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture | Q43263229 | ||
| Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study | Q43919658 | ||
| Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. | Q44193794 | ||
| Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes | Q44526985 | ||
| Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes | Q44599736 | ||
| Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study | Q44686996 | ||
| Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance | Q44831737 | ||
| Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts | Q44841302 | ||
| Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective po | Q44953905 | ||
| beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis | Q45105931 | ||
| Sulfonylurea induced beta-cell apoptosis in cultured human islets | Q45105959 | ||
| GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. | Q46088562 | ||
| Physiological and molecular determinants of insulin action in the baboon. | Q46823836 | ||
| Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis. | Q51245616 | ||
| Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. | Q51616532 | ||
| Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. | Q53964243 | ||
| GLP-1 Receptor in Pancreatic α Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner | Q58616051 | ||
| Dimorphic histopathology of long-standing childhood-onset diabetes | Q60174070 | ||
| GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts | Q60192351 | ||
| Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial | Q64355404 | ||
| Lipolytic action of glucagon-like peptides in isolated rat adipocytes | Q67491311 | ||
| A social tethering system for nonhuman primates used in laboratory research | Q68472537 | ||
| Cellular composition of the human diabetic pancreas | Q70269326 | ||
| Expression of c-Kit receptor tyrosine kinase and effect on beta-cell development in the human fetal pancreas | Q80370144 | ||
| ADOPT: lessons from comparison of glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q80426417 | ||
| Anti-inflammatory properties of exenatide in human pancreatic islets | Q84349939 | ||
| P433 | issue | 20 | |
| P921 | main subject | hamadryas baboon | Q189484 |
| P577 | publication date | 2019-10-17 | |
| P1433 | published in | JCI insight | Q27727187 |
| P1476 | title | Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas | |
| P478 | volume | 4 |
Search more.